Fortress Biotech
Fortress Biotech's revenue rose 9.7% to $63 million in fiscal 2025. Its operating margin was −111.0%, up from −191.4% a year earlier. It paid out $1 million in dividends and buybacks. The diluted share count rose 34.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Fortress Biotech does
Fortress Biotech is a drug company that licenses or buys the rights to medicines and drug candidates, often from universities and research hospitals, and develops them through a group of subsidiaries and partner companies it controls. Some of those companies are listed on their own, such as Journey Medical and Mustang Bio. Fortress aims to earn money from product sales, from the shares it holds in these companies, and from royalties and payments when it sells or licenses a drug to a larger company.
Its only revenue from selling medicines comes through Journey Medical, which markets prescription skin treatments in the United States, including Emrosi and Zilxi for rosacea, Amzeeq and Accutane for acne, and Qbrexza for heavy underarm sweating. Its other programs are still in development.
Fortress has also earned money by selling companies and rights. In May 2025 Sun Pharma bought its former subsidiary Checkpoint, and Fortress received $28.0 million and a royalty on sales of Checkpoint's skin-cancer drug. In January 2026 the FDA approved ZYCUBO, a copper treatment for children with Menkes disease developed by its subsidiary Cyprium, which then agreed to sell a related FDA priority review voucher for $205 million. At the end of 2025 Fortress and its companies had 78 full-time employees.
Its biggest risks, as it describes them
- Most of its drug candidates are at an early stage and may never be approved or sold.
- It has a history of losses and may need more money, which could dilute shareholders or force it to cut programs.
- Sales of Journey's skin products could fall, including as they face generic competition.
- Its heavy reliance on outside firms to develop, make and test its products, and on licenses for most of its technology.
- Some of its executives also run its partner companies and control its direction, which could create conflicts of interest.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 306 | 178 | 81 | 57 | 79 |
| Debt incl. finance leases | 43 | 92 | 61 | 58 | 52 |
| Net debt (negative means net cash) | −263 | −87 | −20 | 1 | −27 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.4x | 2.2x | 2.7x | 2.5x | 1.1x |
| Interest coverage | −12.3x | −16.3x | −9.3x | −8.2x | −7.0x |
| Current ratio | 3.4x | 1.8x | 1.4x | 1.3x | 2.5x |
| Quick ratio | 3.3x | 1.7x | 1.3x | 1.1x | 2.3x |
Cash flow
Projections
Project Fortress Biotech's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $340,398 of Fortress Biotech shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 19, 2026 | Lindsay A Md RosenwaldPresident, CEO & Chairman, Director, 10% owner | Bought | 17,456 | $1.86 | $32,440 | Form 4 |
| Nov 19, 2026 | David JinChief Financial Officer | Bought | 7,605 | $1.87 | $14,221 | Form 4 |
| Nov 18, 2026 | Lindsay A Md RosenwaldPresident, CEO & Chairman, Director, 10% owner | Bought | 54,776 | $1.90 | $104,233 | Form 4 |
| Nov 18, 2026 | David JinChief Financial Officer | Bought | 25,000 | $1.91 | $47,798 | Form 4 |
| Nov 17, 2026 | Lindsay A Md RosenwaldPresident, CEO & Chairman, Director, 10% owner | Bought | 64,491 | $1.80 | $115,910 | Form 4 |
| Nov 17, 2026 | David JinChief Financial Officer | Bought | 15,000 | $1.72 | $25,796 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 1 of 9 | 6 of 9 |
| Rule of 40 | −140.2% | −170.8% | — |
| Altman Z'' | −17.96 | −21.04 | −12.29 |
| Accruals ratio | 29.3% | 21.9% | 44.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 1 of 9 | 6 of 9 |
Compare
Put Fortress Biotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Fortress Biotech | FY25 | 9.7% | −111.0% | — | −323.7% | — | 6 | |
| Enanta Pharmaceuticals | FY26 | −3.6% | −99.0% | −67.9% | — | — | — | Compare |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
| Journey Medical | FY25 | 10.2% | −13.2% | — | −22.4% | — | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 16 | 17 | 27 | 37 | 46 | 69 | 76 | 84 | 58 | 63 |
| Revenue growth | 1,809.6% | 4.6% | 55.9% | 36.3% | 24.5% | 50.9% | 10.1% | 11.6% | −31.8% | 9.7% |
| Gross profit | 16 | 14 | 21 | 26 | 31 | 37 | 45 | 62 | 37 | 42 |
| Research and development | 35 | 48 | 87 | 81 | 64 | 129 | 135 | 106 | 57 | 12 |
| Operating income | −66 | −90 | −120 | −111 | −94 | −188 | −204 | −142 | −110 | −70 |
| Net income | −55 | −67 | −84 | −40 | −46 | −65 | −87 | −61 | −46 | 7 |
| Diluted EPS (US$) | −20.70 | −24.15 | −29.10 | −10.95 | −9.75 | −11.85 | −15.97 | −8.47 | −2.69 | −0.07 |
| Diluted shares (millions) | 3 | 3 | 3 | 4 | 5 | 5 | 6 | 8 | 21 | 28 |
| Cash flow | ||||||||||
| Cash from operations | −46 | −81 | −99 | −95 | −84 | −116 | −179 | −128 | −80 | −66 |
| Capital expenditure | 6 | 1 | 7 | 2 | 2 | 5 | 3 | 0 | 0 | — |
| Free cash flow | −52 | −82 | −106 | −97 | −86 | −121 | −182 | −128 | −80 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 12 | 13 | 15 | 13 | 14 | 20 | 23 | 17 | 33 | 29 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 88 | 131 | 83 | 137 | 233 | 306 | 178 | 81 | 57 | 79 |
| Debt incl. finance leases | 30 | 68 | 84 | 85 | 52 | 43 | 92 | 61 | 58 | 52 |
| Total assets | 171 | 246 | 141 | 226 | 333 | 396 | 294 | 168 | 144 | 186 |
| Total liabilities | 88 | 125 | 121 | 154 | 136 | 171 | 244 | 166 | 146 | 123 |
| Shareholders' equity | 38 | 53 | 2 | 26 | 100 | 109 | 42 | 22 | 23 | 50 |
| Margins and ratios | ||||||||||
| Gross margin | 95.2% | 78.8% | 77.2% | 71.2% | 68.0% | 53.4% | 59.4% | 72.9% | 63.8% | 66.9% |
| Operating margin | −398.7% | −520.7% | −446.4% | −302.5% | −206.7% | −274.1% | −268.8% | −168.4% | −191.4% | −111.0% |
| Net margin | −334.3% | −387.8% | −313.0% | −109.1% | −102.0% | −94.1% | −114.3% | −71.8% | −79.8% | 10.8% |
| Free cash flow margin | −316.6% | −475.2% | −394.1% | −265.6% | −187.7% | −176.1% | −240.4% | −151.8% | −139.0% | — |
| Rule of 40 (growth + FCF margin) | 1,493.0% | −470.6% | −338.2% | −229.4% | −163.2% | −125.2% | −230.3% | −140.2% | −170.8% | — |
| Return on capital | −296.6% | −173.0% | −242.7% | −423.3% | — | — | — | — | — | −323.7% |
| Return on equity | −115.6% | −146.9% | −309.2% | −284.8% | −73.5% | −61.9% | −115.1% | −188.7% | −203.2% | 18.8% |
| Return on assets | −38.1% | −32.1% | −43.5% | −21.8% | −16.6% | −17.7% | −25.1% | −26.3% | −29.5% | 4.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |